Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Korro Bio, Inc. Director's Dealing 2023

Aug 14, 2023

33032_dirs_2023-08-14_9313c3be-126e-4537-8366-640fff5e2044.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Frequency Therapeutics, Inc. (FREQ)
CIK: 0001703647
Period of Report: 2023-08-10

Reporting Person: Mitrano Richard J. (VP Finance & Operations)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-08-10 Common Stock S 247 $.64 Disposed 50091 Direct
2023-08-11 Common Stock S 240 $.64 Disposed 49851 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 4032 Indirect

Footnotes

F1: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person.

F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.642 to $0.661. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

F3: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.636 to $0.641. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.